-- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET -- NEWTON, Mass.

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NEWTON, Mass., Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia

Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio

Dow up 0.38%, NASDAQ up 0.25%, S&P 500 up 0.22%. Consumer discretionary shares up 5.6%, material

Piper Sandler analyst Edward Tenthoff maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Over

US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon sh

Wall Street analysts changed outlook on top names. Check ratings page for upgrades, downgrades, init

Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Kar

Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-

Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See wha

Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades

HC Wainwright & Co. analyst Robert Burns downgrades Karyopharm Therapeutics (NASDAQ:KPTI) fro

Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pr

Karyopharm stock plunged after hours after its Phase 3 endometrial cancer trial missed the primary e

Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

A trend favoring the selinexor arm was observed in the modified intent to treat (mITT) population (n

– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Comp

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review – – Following FDA Eng

– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) – – A Trend Favorin

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being hi

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's

NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia

NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia

Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxol

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-B

– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Ac

– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achie

NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia

– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial – – Conf

NEWTON, Mass., May 28, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia

The consensus price target hints at a 70.5% upside potential for Karyopharm Therapeutics (KPTI). Whi

Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript

Karyopharm Therapeutics NASDAQ: KPTI said it entered 2026 with several near-term clinical and regula

Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1